SES-S.A.
29.3.2022 08:52:05 CEST | Business Wire | Press release
The latest contract awarded by the European Maritime Safety Agency (EMSA) will see the agency continue to use SES’s high-performance satellite connectivity services for Remotely Piloted Aircraft Systems’ (RPAS) operations, SES and EMSA announced today. Under the new agreement, SES’s managed connectivity service will allow end-users to receive and exchange RPAS data in near real-time and support the operational needs of missions at sea.
SES has been a longstanding partner of EMSA in delivering integrated maritime services that support the EU’s objectives of creating a safe, secure, green and competitive maritime sector. The new multi-year contract follows a previously-awarded agreement that enabled multiple EMSA missions with the guaranteed high-performance connectivity service for pollution monitoring, maritime safety and general maritime surveillance.
Under the new framework agreement, SES will leverage its extensive government SATCOM Ku-, Ka- and military-Ka band capacity and ground segment to continue delivering connectivity services for EMSA’s RPAS missions across multiple coastal regions of the European Union. The service will be enabling Long Endurance Remotely Piloted Aircraft Systems for medium and long-range operations. In addition, the GovSatCom-grade service will bring connectivity to the ships, enabling data-intensive applications such as distribution of audiovisual RPAS mission data, secure access to the network and connection to the headquarters on land to ensure timely decision-making.
The connectivity solution provided to EMSA is based on the REACH platform, a new capability developed by SES specifically for European governmental and institutional users requiring fast, flexible, reliable and secure connectivity. The platform allows for GovSatCom-level service for safety, security and emergency response applications.
“With the rise in number of sensors used in the RPAS missions and the subsequent additional data information flow, we require GovSatCom-level capabilities that can quickly and flexibly respond to our growing performance, security and coverage needs to support our users. We are very pleased to continue working with SES to ensure maritime safety of the European Union,” said Maja Markovčić Kostelac, Executive Director of EMSA.
“As the European Union is increasingly adopting RPAS for the maritime missions, it is our priority to deliver the fully-managed high-performance GovSatCom-grade service leveraging SES’s space and ground infrastructure, and global multi-band, multi-frequency coverage. This enables the end user with the information and tools they need to carry out safe and successful missions, including remote monitoring and real-time situational awareness,” said Philippe Glaesener, Senior Vice President for Defence, Security and Institutions at SES. “And we do not stop here. SES continues putting in place innovative multi-orbit solutions, further expanding government services to meet the growing demand.”
The new agreement with EMSA will allow the European Union member states to access SES’s extensive Ku- and Ka- bands on seven SES satellites, as well as the GovSat-1 satellite’s government military-Ka band and GovSat’s secure missions operations centre in Europe. SES is the only company that operates a total of 70 satellites including over 50 geostationary as well as 20 non-geostationary Medium Earth Orbit satellites providing carrier-grade SATCOM connectivity globally.
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About EMSA
The European Maritime Safety Agency (EMSA) is a decentralised agency of the EU, based in Lisbon, Portugal. EMSA serves the EU’s maritime interests for a safe, secure, green and competitive maritime sector, delivering value for member states through support for pollution prevention and response, maritime surveillance, safety and security, digitalisation and the provision of integrated maritime services, and technical assistance.
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,400 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005693/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom